Monocrixo L.P. (Une Prise Quotidienne) (Tramadol Hydrochloride)

Tramadol Hydrochloride, the active ingredient in Monocrixo L.P. (Une Prise Quotidienne), is an opioid analgesic presented as an oral tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Monocrixo L.P. (Une Prise Quotidienne) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Tramadol Hydrochloride is used to treat pain conditions that involve the central nervous system. - Acute postoperative pain: provides analgesia to reduce pain after surgical procedures. - Chronic musculoskeletal pain: helps control persistent pain associated with conditions such as osteoarthritis. - Cancer‑related pain: contributes to moderate to severe pain relief in oncology patients.

Tramadol Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Dizziness: sensation of light‑headedness or unsteadiness. - Constipation: reduced bowel movements. - Headache: mild to moderate cranial pain. - Somnolence: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Seizures: risk of convulsive episodes, especially at high doses. - Respiratory depression: reduced breathing effort that may be life‑threatening. - Serotonin syndrome: symptoms such as agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents. - Allergic reactions: rash, itching, or anaphylaxis. - Dependence or abuse potential: risk of developing physical or psychological dependence with prolonged use.

When prescribing Tramadol Hydrochloride, clinicians should consider several safety measures to minimize risk. - Assess renal and hepatic function: adjust use in patients with impaired clearance. - Evaluate seizure history: avoid or monitor in individuals with epilepsy. - Review concomitant serotonergic drugs: risk of serotonin syndrome. - Monitor for signs of respiratory depression: especially in opioid‑naïve patients. - Counsel on driving and operating machinery: impairment may occur. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Tramadol Hydrochloride interacts with several medication classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: can precipitate severe serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): increase risk of respiratory depression and sedation. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: may heighten serotonin toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): reduce conversion to active metabolite, decreasing analgesic effect. - Anticonvulsants (e.g., carbamazepine): may lower tramadol levels. - Diuretics: may enhance risk of hyponatremia.